CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Quantity Limit Exception — Approval Criteria

Defines criteria and requirements for approving exceptions to drug quantity limits for Neighborhood Health Plan of Rhode Island members (Medicaid and Commercial). Affects providers requesting higher-than-standard quantities or dosing for covered drugs.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyQuantity Limit Exception — Approval Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective Date4/2019

Next Review DateN/A

Key ActionProvide indication, dose/quantity, and supporting documentation that justifies the requested excess quantity (for example: weight/BSA, failed lower regimens, start date for continuation, or specific drug interaction).

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthsmaximum authorization duration

4/2019effective date

7review entries

Medicaid, Commercialplan scope

Quantity Limit Exception — Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Quantity Limit Exception — Approval Criteria

An authorization may be granted when ALL of the following criteria are met:

A: Requested drug/product is for an FDA-approved indication or a medically accepted indication documented in AHFS-DI, Micromedex DrugDex, Clinical Pharmacology, Lexi-Drugs, or peer-reviewed literature.

B: Prescribed dose and quantity fall within FDA-approved labeling or compendia-supported dosing guidelines.

a: Requested dose/frequency is a loading dose for initiation of therapy.
b: Patient is dosed by weight or BSA and requires greater quantity to achieve appropriate dose; patient weight/BSA must be provided.
c: Patient requires additional quantities of a lower strength due to intolerance to higher strength maintenance dosing; rationale must be provided.
d: Patient requires greater quantity to adjust dose/frequency due to a drug interaction; specific interaction must be provided.
e: Request is for continuation of therapy at the requested dose where patient is stable and not experiencing adverse side effects; start date on requested dose must be provided.
f: Patient tried and failed lower doses of the requested medication and now requires a higher dose; failed regimens must be provided.

An authorization for a quantity limit exception will be considered only when the request satisfies the policy approval criteria. Specifically, the requested product must be for an FDA-approved indication or a medically accepted indication documented in one of the listed compendia (AHFS-DI, Micromedex DrugDex, Clinical Pharmacology, Lexi-Drugs) or supported by peer-reviewed literature. In addition, the prescribed dose and quantity must align with FDA labeling or compendia-supported dosing guidance. Finally, at least one supporting justification for the additional quantity must be provided (examples include loading dose, weight/BSA-based dosing with patient weight/BSA, intolerance to higher strength, adjustment for a drug–drug interaction, continuation of stable therapy with start date, or documented failure of lower doses).

Requests that do not meet all elements of the approval criteria will be considered not covered and may be denied. Common reasons for denial include lack of a medically accepted or FDA-approved indication documented in the accepted compendia or literature, dosing or quantity that fall outside FDA or compendia guidance, or failure to provide required supporting information for one of the justifications in criterion C (for example, missing patient weight/BSA for weight‑based dosing, no rationale for intolerance, no start date for continuation, or no documentation of failed lower regimens).

Provider Requirements and Authorization Notes

Prior Authorization

Quantity-limit exception authorization criteria

Prior authorization for quantity-limit exception may be granted when the requested drug is being used for an FDA‑approved indication or a medically-accepted compendia-supported indication, and the prescribed dose and quantity fall within FDA‑approved labeling or compendia-supported dosing guidelines. Requests may also be approved when one of the following applies: the request is for a loading dose for initiation of therapy; the drug is weight- or BSA-dosed and a greater quantity is needed to achieve the appropriate dose (patient weight/BSA required); additional quantities of a lower strength are needed because the patient cannot tolerate the higher strength (provide rationale); a greater quantity is needed to adjust dose or frequency because of a drug–drug interaction (specify interaction); continuation of therapy at the requested dose for a patient who is stable and not experiencing adverse effects (provide start date on requested dose); or the patient tried and failed lower doses and now requires a higher dose (provide failed regimens).

Requests must document the FDA‑approved or compendia-supported indication (cite compendia when applicable).
Prescribed dose and total quantity must be consistent with product labeling or recognized compendia dosing guidance.
When approval is sought under exception criteria, include supporting documentation: patient weight/BSA for weight‑based dosing, start date of therapy for continuation requests, rationale for intolerance to higher strength, details of the specific drug–drug interaction, and documentation of prior failed lower-dose regimens.
Step therapy: when a higher dose or greater quantity is requested based on failure of lower-dose therapy, include documentation of the lower-dose regimens tried and why they failed (lack of efficacy, intolerance, adverse events).

Step Therapy

Step therapy notes

When a higher dose or larger quantity is requested, the request must include clinical documentation that lower-dose or preferred-step therapies were tried and failed unless one of the approved exception reasons applies (loading dose, weight/BSA dosing, intolerance to higher strength, drug interaction, continuation of stable therapy). Failure documentation should include regimen details (dose, duration, and reason for failure).

Document each prior regimen tried (drug name, dose, start/stop dates, and reason for discontinuation).
If failure was due to adverse effects or intolerance, provide description and actions taken.
If failure was due to lack of efficacy, provide objective measures or clinical notes supporting lack of response.

Documentation Required

Required documentation

Providers must supply sufficient documentation to support the requested dose/quantity and the rationale for an exception. Required documentation includes the indication, current and prior dosing regimens with dates, any relevant laboratory or clinical data, patient weight and/or BSA when applicable, start date of current dose for continuation requests, and specifics of any drug–drug interaction or intolerance.

Indication and citation to FDA labeling or compendia (AHFS‑DI, Micromedex DrugDex, Clinical Pharmacology, Lexi‑Drugs, or peer‑reviewed literature).
Dose and total quantity requested with units and duration.
Supporting clinical documentation: prior treatment history, lab results, weight/BSA, start date on current dose, and rationale for exception.

Denial Risk

Denial triggers for quantity exceptions

Requests that do not meet the criteria will be denied. Common denial triggers include: use for indications not supported by FDA labeling or recognized compendia, doses or quantities outside of labeling/compendia guidance without an approved exception reason, lack of documentation of prior lower-dose therapy when required, missing patient weight/BSA for weight‑based dosing, or insufficient detail about drug interactions or intolerance.

Denial if indication is not FDA‑approved or unsupported by listed compendia.
Denial if prescribed dose/quantity exceed labeling or compendia guidance without adequate exception documentation.
Denial if prior-step therapy failure is asserted but not documented (regimen, duration, reason).
Denial if required supporting details (weight/BSA, start date, interaction specifics, rationale) are not provided.

Background

This policy expects that use of the requested drug/product be FDA‑approved or supported by a medically accepted indication documented in one of the recognized compendia or peer‑reviewed literature. No specific clinical conditions, disease states, or drug classes are defined in this document; the focus is on ensuring indication and dosing are consistent with FDA labeling or accepted compendia and that acceptable clinical justification is provided when quantities beyond standard limits are requested.

Key Definitions

Medically accepted indication

DefinitionMedically accepted indication: use supported by one of the listed standard reference compendia (AHFS-DI, Thomson Micromedex DrugDex, Clinical Pharmacology, Wolters Kluwer Lexi-Drugs) or peer-reviewed published medical literature demonstrating sufficient evidence to support use.

Accepted compendiaAmerican Hospital Formulary Service Drug Information (AHFS-DI); Thomson Micromedex DrugDex; Clinical Pharmacology; Wolters Kluwer Lexi-Drugs.

Evidence standardPeer‑reviewed published medical literature that indicates sufficient evidence exists to support use.

Use in approval criteriaMedically accepted indication qualifies the requested drug/product for quantity limit exception when documented from one of these compendia or peer‑reviewed literature.

Initial Therapy Justification

Initial therapy justification — loading doses or weight-based dosing requiring extra quantity

Initial therapy considerations included as allowable justification when loading doses or weight-based dosing require extra quantity.

Initial: Loading dose for initiation or weight/BSA-based dosing requiring greater quantity (patient weight/BSA must be provided).

Continuation Therapy Justification

Continuation of therapy — supported justification when patient stable on requested dose

Continuation of therapy is an acceptable justification for a quantity limit exception when the member is stable on the requested dose.

Continuation: Request is for continuation of therapy on the requested dose where patient is stable and not experiencing any adverse side effects; start date of therapy on requested dose must be provided.

Step Therapy Requirements

Step	Requirement
1
Provide documentation of trial and failure of lower dose regimens of the requested medication when applicable; failed regimens must be provided.

Quantity Limit Details

Authorization duration for quantity limit exceptions

Maximum authorization durationUp to 12 months per approval.

Determination basisDuration determined consistent with FDA guidance and internal policies and procedures.

ScopeApplies to drugs with a quantity limit as described in the Quantity Limit Exception policy.